END's Role in Cellular Processes (P41395)

Target Name: Endothiapepsin

NCBI ID: P41395

Endothiapepsin

Other Name(s): Endothiapepsin | Aspartic protease

END's Role in Cellular Processes

Endothiapepsin (END) is a peptide that is found in the endoplasmic reticulum (ER) of all living cells. It is a 21-kDa protein that belongs to the family of enzymes known as metal-尾-lactamases (MBLs). MBLs are a group of enzymes that are involved in the catalytic reduction of 尾-lactam acids to 尾-hydroxy-尾-lactam acids, which is a key step in the production of many different types of peptides and proteins.

END is unique in that it is able to hydrolyze the 尾-lactamate bond located in the N-terminus of its precursor peptide, which is the 尾-lactamate bond that is responsible for the unique properties and functions of many different proteins. This ability to hydrolyze the 尾-lactamate bond allows END to be involved in the regulatory and intracellular signaling processes that are important for the proper functioning of many different cell types.

END is expressed in many different tissues and cells throughout the body, including the brain, heart, liver, and pancreas. It is also highly expressed in the placenta, which is responsible for providing nutrients and oxygen to the developing fetus. This suggests that END may be involved in the regulation of fetal development and growth, and could potentially be a drug target or biomarker for a variety of diseases.

END has also been shown to play a role in the regulation of cellular signaling pathways that are important for many different cellular processes, including cell growth, apoptosis (programmed cell death), and inflammation. For example, END has been shown to be involved in the regulation of the TGF-β pathway, which is involved in the regulation of cell growth, apoptosis, and many other cellular processes.

END is also involved in the regulation of the NF-kappa-B pathway, which is involved in the regulation of inflammation and other cellular processes. This suggests that END may be involved in the regulation of inflammatory responses and could potentially be a therapeutic target for a variety of diseases.

END has also been shown to be involved in the regulation of the cell signaling pathway known as the PI3K/AKT pathway. This pathway is involved in the regulation of many different cellular processes, including cell survival, angiogenesis (the formation of new blood vessels), and inflammation.END has been shown to be involved in the regulation of this pathway, which suggests that it may be involved in the regulation of cellular processes that are important for the survival and survival of many different cell types.

In conclusion, END is a unique and highly expressed protein that is involved in the regulation of many different cellular processes. Its ability to hydrolyze the 尾-lactamate bond in its precursor peptide and its involvement in the TGF-β, NF-kappa-B, and PI3K/AKT pathways suggest that it may be a drug target or biomarker for a variety of diseases. Further research is needed to fully understand the role of END in cellular processes and its potential as a therapeutic target.

Protein Name: Endothiapepsin (nonspecified Subtype)

The "Endothiapepsin Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about Endothiapepsin comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets